Search results for "Cotreatment"

showing 1 items of 1 documents

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

2018

Abstract Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored. Current options include new pituitary surgery and/or radiosurgery, or alternative medical treatment with SRLs high dose regimens, pegvisomant (PEG) as monotherapy, or combined therapy with the addition of PEG or cabergoline to SRLs. A new pharmacological approach includes pasireotide, a second-generation SRL approved for patients who do not adequately respond to surgery and/or for whom surgery is not an option. No reports on efficacy and safety of combined therapy with pasireotide and p…

OncologyAdultMalemedicine.medical_specialtyCabergolineEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPegvisomant030209 endocrinology & metabolismCase ReportAntineoplastic Agentslcsh:Diseases of the endocrine glands. Clinical endocrinologyRadiosurgerySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCombined treatmentCabergolineInternal medicineAcromegalymedicineHumansErgolinesSalvage TherapyCotreatmentlcsh:RC648-665Medical treatmentSomatostatin receptorbusiness.industryHuman Growth HormoneGeneral Medicinemedicine.diseasePrognosisResistantPasireotideHormonesPasireotidechemistry030220 oncology & carcinogenesisPegvisomantAcromegalyDrug Therapy CombinationAcromegaly; Cotreatment; Pasireotide; Pegvisomant; ResistantbusinessSomatostatinmedicine.drugBMC Endocrine Disorders
researchProduct